Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Caribou Biosciences, Inc.CRBU · Entity 6445 | Director | February 20, 2026 | February 20, 2026 |
| Metacrine, Inc.MTCR · Entity 115177 | Director | May 18, 2022 | September 06, 2022 |
| Vaxcyte, Inc.PCVX · Entity 1164 | PRESIDENT AND CFO | September 08, 2026 | September 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Caribou Biosciences, Inc.
Report date February 20, 2026 · Filed February 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $1.80 · Expires 2036-02-19 | Direct | 45,000 |
Reported balance
After 2026-02-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-20 · Grant · Acquired 45,000 · Balance 45,000 F1: One-twelfth of the shares subject to this option will vest on each monthly anniversary of the grant date such that the option will be fully vested on February 20, 2027, subject to the reporting person continuing to provide service to the Issuer through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: One-twelfth of the shares subject to this option will vest on each monthly anniversary of the grant date such that the option will be fully vested on February 20, 2027, subject to the reporting person continuing to provide service to the Issuer through each such vesting date.
Metacrine, Inc.
Report date May 18, 2022 · Filed September 06, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.42 · Expires 2032-05-17 | Direct | 16,500 |
Reported balance
After 2022-05-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-05-18 · Grant · Acquired 16,500 · Balance 16,500 F1: The shares subject to the option shall vest on the earlier of (i) the one-year anniversary of the date of grant or (ii) the day immediately prior to the date of the Issuer's 2023 annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option shall vest on the earlier of (i) the one-year anniversary of the date of grant or (ii) the day immediately prior to the date of the Issuer's 2023 annual meeting of stockholders.
Vaxcyte, Inc.
Report date September 08, 2026 · Filed September 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 95,316 |
Reported balance
After 2026-09-08 transaction · row 1
1 source rowRow 1 · 2026-09-08 · Tax withholding · Disposed 7,155 · Balance 95,316 F1: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 61,850 |
Reported balance
Holding disclosure · report date 2026-09-08 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 61,850 F2: Shares are held by ALG 2025 GRAT HOLDINGS LLC, of which 100% of the limited liability company interest is owned by a grantor retained annuity trust, of which the Reporting Person is the annuitant and the trustee. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs.
F2: Shares are held by ALG 2025 GRAT HOLDINGS LLC, of which 100% of the limited liability company interest is owned by a grantor retained annuity trust, of which the Reporting Person is the annuitant and the trustee.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Dermira, Inc.
Report date February 20, 2020 · Filed February 25, 2020
Section 16 reporting ended · disclosed 2020-02-25. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 1
1 source rowRow 1 · 2020-02-20 · Disposition to issuer · Disposed 41,951 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Includes 1,024 shares of Dermira Common Stock acquired by the Reporting Person pursuant to Dermira's Employee Stock Purchase Plan. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.51 · Expires 2024-06-04 | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-02-20 · Disposition to issuer · Disposed 120.513 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2024-10-01 | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-02-20 · Disposition to issuer · Disposed 73,287 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2024-10-01 | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-02-20 · Disposition to issuer · Disposed 67,240 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.37 · Expires 2026-02-04 | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-02-20 · Disposition to issuer · Disposed 71,250 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. |
| Employee Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.84 · Expires 2027-02-16 | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-02-20 · Disposition to issuer · Disposed 71,250 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. |
| Employee Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.25 · Expires 2028-02-15 | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2020-02-20 · Disposition to issuer · Disposed 57,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. |
| Employee Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.42 · Expires 2029-02-11 | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2020-02-20 · Disposition to issuer · Disposed 65,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2020-02-20 · Disposition to issuer · Disposed 3,562 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F4: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2020-02-20 · Disposition to issuer · Disposed 5,700 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F4: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2020-02-20 · Disposition to issuer · Disposed 25,000 · Balance 0 F4: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price. F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2020-02-20 · Disposition to issuer · Disposed 15,000 · Balance 0 F4: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price. F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes.
F2: Includes 1,024 shares of Dermira Common Stock acquired by the Reporting Person pursuant to Dermira's Employee Stock Purchase Plan.
F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time.
F4: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 18, 2024 Filed Nov 19, 2024 21:43 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 1,757 | $86.49 | $151,955.90 |
DisclosureSEC source: 0001649094-24-000112 · wk-form4_1732052574.xml · nonDerivative · entry 3 GUGGENHIME ANDREW · CIK 0001230724 · PRESIDENT AND CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 109,623 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted May 17, 2024. F3 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $85.97 to $86.865. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 18, 2024 Filed Nov 19, 2024 21:43 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 6,111 | $85.60 | $523,071.05 |
DisclosureSEC source: 0001649094-24-000112 · wk-form4_1732052574.xml · nonDerivative · entry 2 GUGGENHIME ANDREW · CIK 0001230724 · PRESIDENT AND CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 111,380 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted May 17, 2024. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $84.97 to $85.965. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 18, 2024 Filed Nov 19, 2024 21:43 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 8,000 | $5.35 | $42,800.00 |
DisclosureSEC source: 0001649094-24-000112 · wk-form4_1732052574.xml · nonDerivative · entry 1 GUGGENHIME ANDREW · CIK 0001230724 · PRESIDENT AND CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 117,491 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 07, 2024 Filed Nov 9, 2024 01:47 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantPerformance Restricted Stock Units · Derivative | 35,661 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001649094-24-000106 · wk-form4_1731116819.xml · derivative · entry 2 GUGGENHIME ANDREW · CIK 0001230724 · PRESIDENT AND CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,661 Underlying: Common Stock · 35,661 shares Expires 2034-11-06 F2 · derivative.exercise_date: Represents the target number of shares of Issuer's Common Stock underlying an award of performance restricted stock units ("PSUs"). Each PSU represents the contingent right to receive one share of the Issuer's Common Stock. The attainment of the performance vesting condition will be based on the Issuer's percentile rank within a peer group based on total shareholder return ("TSR") during a four-year performance period that commenced on November 7, 2024, the Grant Date, subject to the Reporting Person's continuous service with the Issuer through completion of the performance period. The actual number of shares of the Issuer's Common Stock deliverable with respect to the award varies based on performance and ranges from 0% to 250% of the target number of shares. Read SEC document |
| November 07, 2024 Filed Nov 9, 2024 01:47 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantPerformance Stock Option (right to buy) · Derivative | 87,481 | $0.00 Strike: $102.70 | $0.00 |
DisclosureSEC source: 0001649094-24-000106 · wk-form4_1731116819.xml · derivative · entry 1 GUGGENHIME ANDREW · CIK 0001230724 · PRESIDENT AND CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,481 Underlying: Common Stock · 87,481 shares Expires 2034-11-06 F1 · derivative.exercise_date: As part of a company-wide grant to all eligible employees of the Issuer, on November 7, 2024 (the "Grant Date"), the Reporting Person was granted a performance stock option to purchase 87,481 shares of the Issuer's Common Stock at a per share exercise price of $102.70. The option is subject to (1) a service-based vesting condition (vesting as to one-third of the shares on each of the third, fourth and fifth anniversaries of the Grant Date) and (2) a performance-vesting condition (which generally requires that the trading price of the Issuer's Common Stock average, over a one-year period, is at least $154.05 (150% of the Grant Date closing price)). Read SEC document |
| October 25, 2024 Filed Oct 28, 2024 21:11 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 19,108 | $0.00 Strike: $20.93 | $0.00 |
DisclosureSEC source: 0001649094-24-000084 · wk-form4_1730149905.xml · derivative · entry 2 GUGGENHIME ANDREW · CIK 0001230724 · PRESIDENT AND CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,892 Underlying: Common Stock · 19,108 shares Expires 2031-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/48 of the shares subject to the option vested on May 1, 2021, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date. Read SEC document |
| October 25, 2024 Filed Oct 28, 2024 21:11 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 19,108 | $20.93 | $399,930.44 |
DisclosureSEC source: 0001649094-24-000084 · wk-form4_1730149905.xml · nonDerivative · entry 1 GUGGENHIME ANDREW · CIK 0001230724 · PRESIDENT AND CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,491 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares are subject to the restrictions on transfer set forth in a Lock-Up Agreement dated September 4, 2024. Read SEC document |
| October 18, 2024 Filed Oct 22, 2024 20:11 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 14,000 | $0.00 Strike: $5.35 | $0.00 |
DisclosureSEC source: 0001649094-24-000082 · wk-form4_1729627909.xml · derivative · entry 10 GUGGENHIME ANDREW · CIK 0001230724 · PRESIDENT AND CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 278,827 Underlying: Common Stock · 14,000 shares Expires 2030-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 1/4 of the shares subject to the option vested on May 1, 2021, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| October 18, 2024 Filed Oct 22, 2024 20:11 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $5.35 | $0.00 |
DisclosureSEC source: 0001649094-24-000082 · wk-form4_1729627909.xml · derivative · entry 9 GUGGENHIME ANDREW · CIK 0001230724 · PRESIDENT AND CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 292,827 Underlying: Common Stock · 12,000 shares Expires 2030-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 1/4 of the shares subject to the option vested on May 1, 2021, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| October 18, 2024 Filed Oct 22, 2024 20:11 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $5.35 | $0.00 |
DisclosureSEC source: 0001649094-24-000082 · wk-form4_1729627909.xml · derivative · entry 8 GUGGENHIME ANDREW · CIK 0001230724 · PRESIDENT AND CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 304,827 Underlying: Common Stock · 8,000 shares Expires 2030-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 1/4 of the shares subject to the option vested on May 1, 2021, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| October 18, 2024 Filed Oct 22, 2024 20:11 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $5.35 | $0.00 |
DisclosureSEC source: 0001649094-24-000082 · wk-form4_1729627909.xml · derivative · entry 7 GUGGENHIME ANDREW · CIK 0001230724 · PRESIDENT AND CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 312,827 Underlying: Common Stock · 8,000 shares Expires 2030-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 1/4 of the shares subject to the option vested on May 1, 2021, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| October 18, 2024 Filed Oct 22, 2024 20:11 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 5,886 | $116.19 | $683,900.23 |
DisclosureSEC source: 0001649094-24-000082 · wk-form4_1729627909.xml · nonDerivative · entry 6 GUGGENHIME ANDREW · CIK 0001230724 · PRESIDENT AND CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 90,383 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted May 17, 2024. F3 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $115.88 to $116.48. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 18, 2024 Filed Oct 22, 2024 20:11 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 36,114 | $115.26 | $4,162,607.98 |
DisclosureSEC source: 0001649094-24-000082 · wk-form4_1729627909.xml · nonDerivative · entry 5 GUGGENHIME ANDREW · CIK 0001230724 · PRESIDENT AND CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 96,269 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted May 17, 2024. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $114.825 to $115.80. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 18, 2024 Filed Oct 22, 2024 20:11 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 14,000 | $5.35 | $74,900.00 |
DisclosureSEC source: 0001649094-24-000082 · wk-form4_1729627909.xml · nonDerivative · entry 4 GUGGENHIME ANDREW · CIK 0001230724 · PRESIDENT AND CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 132,383 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 18, 2024 Filed Oct 22, 2024 20:11 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 12,000 | $5.35 | $64,200.00 |
DisclosureSEC source: 0001649094-24-000082 · wk-form4_1729627909.xml · nonDerivative · entry 3 GUGGENHIME ANDREW · CIK 0001230724 · PRESIDENT AND CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 118,383 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 18, 2024 Filed Oct 22, 2024 20:11 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 8,000 | $5.35 | $42,800.00 |
DisclosureSEC source: 0001649094-24-000082 · wk-form4_1729627909.xml · nonDerivative · entry 2 GUGGENHIME ANDREW · CIK 0001230724 · PRESIDENT AND CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 106,383 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 18, 2024 Filed Oct 22, 2024 20:11 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 8,000 | $5.35 | $42,800.00 |
DisclosureSEC source: 0001649094-24-000082 · wk-form4_1729627909.xml · nonDerivative · entry 1 GUGGENHIME ANDREW · CIK 0001230724 · PRESIDENT AND CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 98,383 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 18, 2024 Filed Sep 19, 2024 21:48 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $5.35 | $0.00 |
DisclosureSEC source: 0001649094-24-000071 · wk-form4_1726782498.xml · derivative · entry 5 GUGGENHIME ANDREW · CIK 0001230724 · PRESIDENT AND CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 320,827 Underlying: Common Stock · 8,000 shares Expires 2030-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 1/4 of the shares subject to the option vested on May 1, 2021, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| September 18, 2024 Filed Sep 19, 2024 21:48 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 829 | $117.53 | $97,433.28 |
DisclosureSEC source: 0001649094-24-000071 · wk-form4_1726782498.xml · nonDerivative · entry 4 GUGGENHIME ANDREW · CIK 0001230724 · PRESIDENT AND CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 90,383 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted June 30, 2023. F4 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $117.11 to $117.89. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 18, 2024 Filed Sep 19, 2024 21:48 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 1,686 | $116.29 | $196,064.94 |
DisclosureSEC source: 0001649094-24-000071 · wk-form4_1726782498.xml · nonDerivative · entry 3 GUGGENHIME ANDREW · CIK 0001230724 · PRESIDENT AND CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 91,212 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted June 30, 2023. F3 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $116.06 to $116.75. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 18, 2024 Filed Sep 19, 2024 21:48 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 5,485 | $115.60 | $634,052.29 |
DisclosureSEC source: 0001649094-24-000071 · wk-form4_1726782498.xml · nonDerivative · entry 2 GUGGENHIME ANDREW · CIK 0001230724 · PRESIDENT AND CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 92,898 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted June 30, 2023. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $115.06 to $115.95. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 18, 2024 Filed Sep 19, 2024 21:48 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 8,000 | $5.35 | $42,800.00 |
DisclosureSEC source: 0001649094-24-000071 · wk-form4_1726782498.xml · nonDerivative · entry 1 GUGGENHIME ANDREW · CIK 0001230724 · PRESIDENT AND CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 98,383 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 21:18 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Tax withholdingCommon Stock | 6,337 | $110.15 | $698,020.55 |
DisclosureSEC source: 0001649094-24-000065 · wk-form4_1725571117.xml · nonDerivative · entry 1 GUGGENHIME ANDREW · CIK 0001230724 · PRESIDENT AND CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,383 F1 · shares: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of restricted stock units. No other shares of common stock subject to the restrictions on transfer set forth in a Lock-Up Agreement dated September 4, 2024 were sold by the Reporting Person. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 20:49 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $5.35 | $0.00 |
DisclosureSEC source: 0001649094-24-000054 · wk-form4_1724186989.xml · derivative · entry 4 GUGGENHIME ANDREW · CIK 0001230724 · PRESIDENT AND CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 328,827 Underlying: Common Stock · 8,000 shares Expires 2030-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 1/4 of the shares subject to the option vested on May 1, 2021, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 20:49 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 3,006 | $79.14 | $237,879.81 |
DisclosureSEC source: 0001649094-24-000054 · wk-form4_1724186989.xml · nonDerivative · entry 3 GUGGENHIME ANDREW · CIK 0001230724 · PRESIDENT AND CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 96,720 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted June 30, 2023. F3 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $78.88 to $79.66. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 20:49 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 4,994 | $78.25 | $390,770.51 |
DisclosureSEC source: 0001649094-24-000054 · wk-form4_1724186989.xml · nonDerivative · entry 2 GUGGENHIME ANDREW · CIK 0001230724 · PRESIDENT AND CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 99,726 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted June 30, 2023. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $77.875 to $78.78. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 20:49 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 8,000 | $5.35 | $42,800.00 |
DisclosureSEC source: 0001649094-24-000054 · wk-form4_1724186989.xml · nonDerivative · entry 1 GUGGENHIME ANDREW · CIK 0001230724 · PRESIDENT AND CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 104,720 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 18, 2024 Filed Jul 22, 2024 20:03 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $5.35 | $0.00 |
DisclosureSEC source: 0001649094-24-000038 · wk-form4_1721678591.xml · derivative · entry 6 GUGGENHIME ANDREW · CIK 0001230724 · PRESIDENT AND CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 336,827 Underlying: Common Stock · 8,000 shares Expires 2030-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: 1/4 of the shares subject to the option vested on May 1, 2021, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| July 18, 2024 Filed Jul 22, 2024 20:03 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 926 | $83.14 | $76,984.86 |
DisclosureSEC source: 0001649094-24-000038 · wk-form4_1721678591.xml · nonDerivative · entry 5 GUGGENHIME ANDREW · CIK 0001230724 · PRESIDENT AND CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 96,720 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted June 30, 2023. F5 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $82.69 to $83.36. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 18, 2024 Filed Jul 22, 2024 20:03 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 1,479 | $82.32 | $121,746.84 |
DisclosureSEC source: 0001649094-24-000038 · wk-form4_1721678591.xml · nonDerivative · entry 4 GUGGENHIME ANDREW · CIK 0001230724 · PRESIDENT AND CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 97,646 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted June 30, 2023. F4 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $81.68 to $82.655. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 18, 2024 Filed Jul 22, 2024 20:03 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 2,500 | $81.06 | $202,637.50 |
DisclosureSEC source: 0001649094-24-000038 · wk-form4_1721678591.xml · nonDerivative · entry 3 GUGGENHIME ANDREW · CIK 0001230724 · PRESIDENT AND CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 99,125 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted June 30, 2023. F3 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $80.65 to $81.625. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 18, 2024 Filed Jul 22, 2024 20:03 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 3,095 | $80.12 | $247,955.93 |
DisclosureSEC source: 0001649094-24-000038 · wk-form4_1721678591.xml · nonDerivative · entry 2 GUGGENHIME ANDREW · CIK 0001230724 · PRESIDENT AND CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 101,625 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted June 30, 2023. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $79.61 to $80.59. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 18, 2024 Filed Jul 22, 2024 20:03 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 8,000 | $5.35 | $42,800.00 |
DisclosureSEC source: 0001649094-24-000038 · wk-form4_1721678591.xml · nonDerivative · entry 1 GUGGENHIME ANDREW · CIK 0001230724 · PRESIDENT AND CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 104,720 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 18, 2024 Filed Jun 21, 2024 00:30 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $5.35 | $0.00 |
DisclosureSEC source: 0001649094-24-000018 · wk-form4_1718929843.xml · derivative · entry 4 GUGGENHIME ANDREW · CIK 0001230724 · PRESIDENT AND CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 344,827 Underlying: Common Stock · 8,000 shares Expires 2030-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 1/4 of the shares subject to the option vested on May 1, 2021, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| June 18, 2024 Filed Jun 21, 2024 00:30 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 348 | $72.56 | $25,249.49 |
DisclosureSEC source: 0001649094-24-000018 · wk-form4_1718929843.xml · nonDerivative · entry 3 GUGGENHIME ANDREW · CIK 0001230724 · PRESIDENT AND CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 96,720 F2 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted June 30, 2023. F4 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $72.48 to $72.60. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 18, 2024 Filed Jun 21, 2024 00:30 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 7,652 | $71.89 | $550,125.24 |
DisclosureSEC source: 0001649094-24-000018 · wk-form4_1718929843.xml · nonDerivative · entry 2 GUGGENHIME ANDREW · CIK 0001230724 · PRESIDENT AND CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 97,068 F2 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted June 30, 2023. F3 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $71.415 to $72.36. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 18, 2024 Filed Jun 21, 2024 00:30 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 8,000 | $5.35 | $42,800.00 |
DisclosureSEC source: 0001649094-24-000018 · wk-form4_1718929843.xml · nonDerivative · entry 1 GUGGENHIME ANDREW · CIK 0001230724 · PRESIDENT AND CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 104,720 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 1,041 shares acquired under the Issuer's Employee Stock Purchase Plan on May 17, 2024. Read SEC document |
| May 20, 2024 Filed May 22, 2024 21:03 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $5.35 | $0.00 |
DisclosureSEC source: 0001415889-24-014108 · form4-05222024_090512.xml · derivative · entry 4 GUGGENHIME ANDREW · CIK 0001230724 · PRESIDENT AND CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 352,827 Underlying: Common Stock · 8,000 shares Expires 2030-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 1/4 of the shares subject to the option vested on May 1, 2021, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| May 20, 2024 Filed May 22, 2024 21:03 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 4,456 | $75.46 | $336,249.76 |
DisclosureSEC source: 0001415889-24-014108 · form4-05222024_090512.xml · nonDerivative · entry 3 GUGGENHIME ANDREW · CIK 0001230724 · PRESIDENT AND CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 95,679 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted June 30, 2023. F3 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $74.95 to $75.88. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 20, 2024 Filed May 22, 2024 21:03 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 3,544 | $74.40 | $263,659.42 |
DisclosureSEC source: 0001415889-24-014108 · form4-05222024_090512.xml · nonDerivative · entry 2 GUGGENHIME ANDREW · CIK 0001230724 · PRESIDENT AND CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 100,135 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted June 30, 2023. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $73.95 to $74.90. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 20, 2024 Filed May 22, 2024 21:03 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 8,000 | $5.35 | $42,800.00 |
DisclosureSEC source: 0001415889-24-014108 · form4-05222024_090512.xml · nonDerivative · entry 1 GUGGENHIME ANDREW · CIK 0001230724 · PRESIDENT AND CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 103,679 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 18, 2024 Filed Apr 22, 2024 20:42 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $5.35 | $0.00 |
DisclosureSEC source: 0001415889-24-011322 · form4-04222024_080406.xml · derivative · entry 4 GUGGENHIME ANDREW · CIK 0001230724 · PRESIDENT AND CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 360,827 Underlying: Common Stock · 8,000 shares Expires 2030-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 1/4 of the shares subject to the option vested on May 1, 2021, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| April 18, 2024 Filed Apr 22, 2024 20:42 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 376 | $61.90 | $23,275.15 |
DisclosureSEC source: 0001415889-24-011322 · form4-04222024_080406.xml · nonDerivative · entry 3 GUGGENHIME ANDREW · CIK 0001230724 · PRESIDENT AND CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 95,679 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted June 30, 2023. F3 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $61.85 to $62.15. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 18, 2024 Filed Apr 22, 2024 20:42 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 7,624 | $61.24 | $466,924.26 |
DisclosureSEC source: 0001415889-24-011322 · form4-04222024_080406.xml · nonDerivative · entry 2 GUGGENHIME ANDREW · CIK 0001230724 · PRESIDENT AND CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 96,055 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted June 30, 2023. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $60.83 to $61.77. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 18, 2024 Filed Apr 22, 2024 20:42 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 8,000 | $5.35 | $42,800.00 |
DisclosureSEC source: 0001415889-24-011322 · form4-04222024_080406.xml · nonDerivative · entry 1 GUGGENHIME ANDREW · CIK 0001230724 · PRESIDENT AND CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 103,679 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 18, 2024 Filed Mar 20, 2024 20:29 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $5.35 | $0.00 |
DisclosureSEC source: 0001415889-24-008745 · form4-03202024_080321.xml · derivative · entry 4 GUGGENHIME ANDREW · CIK 0001230724 · PRESIDENT AND CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 368,827 Underlying: Common Stock · 8,000 shares Expires 2030-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 1/4 of the shares subject to the option vested on May 1, 2021, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| March 18, 2024 Filed Mar 20, 2024 20:29 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 236 | $69.64 | $16,435.51 |
DisclosureSEC source: 0001415889-24-008745 · form4-03202024_080321.xml · nonDerivative · entry 3 GUGGENHIME ANDREW · CIK 0001230724 · PRESIDENT AND CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 95,679 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted June 30, 2023. F3 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $69.625 to $69.66. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 18, 2024 Filed Mar 20, 2024 20:29 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 7,764 | $69.00 | $535,708.24 |
DisclosureSEC source: 0001415889-24-008745 · form4-03202024_080321.xml · nonDerivative · entry 2 GUGGENHIME ANDREW · CIK 0001230724 · PRESIDENT AND CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 95,915 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted June 30, 2023. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $68.58 to $69.495. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 18, 2024 Filed Mar 20, 2024 20:29 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 8,000 | $5.35 | $42,800.00 |
DisclosureSEC source: 0001415889-24-008745 · form4-03202024_080321.xml · nonDerivative · entry 1 GUGGENHIME ANDREW · CIK 0001230724 · PRESIDENT AND CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 103,679 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 02, 2024 Filed Mar 5, 2024 02:20 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Tax withholdingCommon Stock | 3,795 | $71.55 | $271,532.25 |
DisclosureSEC source: 0001415889-24-006473 · form4-03052024_020320.xml · nonDerivative · entry 2 GUGGENHIME ANDREW · CIK 0001230724 · PRESIDENT AND CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,679 F2 · shares: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of restricted stock units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.